 |
| Sent to you from Drugs.com You received this email because you requested to receive drug alerts. Change your notification settings or unsubscribe here. |
Sent to subscribers of: alendronate systemic, etidronate systemic, ibandronate systemic, risedronate systemic, tiludronate systemic, alendronate, etidronate, ibandronate, risedronate, bisphosphonates July 21, 2011 Audience: Geriatrics, Family Practice, Internal Medicine. Includes: Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel (etidronate), and Skelid (tiludronate) ISSUE: FDA notified healthcare professionals and patients about its ongoing review of data from published studies to evaluate whether use of oral bisphosphonate drugs is associated with an increased risk of cancer of the esophagus. FDA has not concluded that taking an oral bisphosphonate drug increases the risk of esophageal cancer. There are insufficient data to recommend endoscopic screening of asymptomatic patients. FDA will continue to evaluate all available data supporting the safety and effectiveness of bisphosphonate drugs and will update the public when more information becomes available.  |
| Copyright © 2011 Drugs.com. All rights reserved. Change your notification settings or unsubscribe here. |
